UCB 34714

The Eleventh Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT XI, took place in Eilat, Israel from the 6th to 10th of May… Expand

SummaryBrivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra®). It possesses a binding affinity for the… Expand

Brivaracetam (ucb 34714; BRV), a new antiepileptic drug (AED) candidate, is a pyrrolidone derivative displaying a markedly higher… Expand

Screening of 12 000 compounds for binding affinity to the synaptic vesicle protein 2A (SV2A), identified a high‐affinity… Expand

Background: Epilepsy is a neurological disorder with a worldwide prevalence estimated to be 0.5 – 1.0% of the population. Many… Expand

BACKGROUND Epilepsy is a neurological disorder with a worldwide prevalence estimated to be 0.5-1.0% of the population. Many… Expand

Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra). It possesses a binding affinity for the synaptic… Expand

Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the… Expand

(S)-alpha-ethyl-2-oxopyrrolidine acetamide 2 (levetiracetam, Keppra, UCB S.A.), a structural analogue of piracetam, has recently… Expand

The Seventh Eilat Conference on New Antiepileptic Drugs (AEDs) (EILAT VII) took place in Villasimius, Sardinia, Italy from the… Expand